1. Tyrosine kinase inhibitor toxicities: A society of gynecologic oncology review and recommendations.
- Author
-
Rimel, Bobbie J., Crane, Erin K., Hou, June, Nakayama, John, MacDonald, Jennifer, Lutz, Kathleen, Makker, Vicky, and O'Cearbhaill, Roisin E.
- Subjects
- *
PROTEIN-tyrosine kinase inhibitors , *GYNECOLOGIC oncology , *ENDOMETRIAL cancer , *GYNECOLOGIC cancer , *DRUG target - Abstract
Oral tyrosine kinase inhibitors (TKIs) have new indications for treatment in gynecologic malignancies. These targeted drugs have both unique and overlapping toxicities, which require careful attention and management. New combination therapies with immune-oncology agents have demonstrated promise in endometrial cancer. This review examines common adverse events associated with TKIs and provides readers with an evidence-based review on current uses and strategies for the management of these medications. A comprehensive review of the medical literature on TKI use in gynecologic cancer was undertaken by a committee approach. Details of each drug, its molecular target, and relevant data on both clinical efficacy and side effects were compiled and organized for clinical use. Information on drug-related secondary effects and management strategies for specific toxicities, including dose reduction and concomitant medications, were gathered. TKIs can potentially offer improved response rates and durable responses for a group of patients who were previously without an effective standard second-line therapy. The combination of lenvatinib and pembrolizumab represents a more targeted approach to the drivers of endometrial cancer; however, there remains significant drug-related toxicity, and thus dose reduction and dose delay are frequently required. Toxicity management requires frequent check-ins and management strategies to help patients find the highest tolerable dose. TKIs are expensive and patient financial toxicity is as critical a measure of a drug's utility as any drug side effect. Many of these drugs have patient assistance programs, which should be fully utilized to minimize cost. Future studies are needed to expand the role of TKIs into new molecularly driven groups. Attention to cost, durability of response, and long-term toxicity management is needed to ensure all eligible patients have access to treatment. • Tyrosine kinase inhibitors are increasingly used as single agents or combined with immunotherapy in gynecologic cancers. • Recognition and appropriate management of their unique toxicities is crucial. • Special considerations for use of TKIs in gynecologic malignancies are reviewed. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF